Symbiotec Pharmalab Limited

Symbiotec Pharmalab Limited

Symbiotec Pharmalab Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026.

Symbiotec Pharmalab Limited

Symbiotec's wholly owned subsidiary Knovea Pharmaceutical enters into a strategic commercialization agreement with a leading global pharmaceutical company for Dual Chamber Vial products in the U.S.

Symbiotec Pharmalab Limited

Symbiotec Pharmalab Limited's wholly owned subsidiary Knovea Pharmaceutical has entered into a strategic commercialization agreement with a leading global pharmaceutical company for Dual Chamber Vial products in the U.S.

Symbiotec Pharmalab Limited

Symbiotec Pharmalab Limited has informed the Exchange regarding the closure of the trading window for insiders due to the upcoming unaudited financial results for the quarter and half year ended September 30, 2026.

Symbiotec Pharmalab Limited

Symbiotec Pharmalab Limited has received an Establishment Inspection Report (EIR) from the U.S. FDA for its manufacturing facility in Pithampur, Madhya Pradesh, India, with a Voluntary Action Indicated (VAI) status.

Symbiotec Pharmalab Limited

Symbiotec Pharmalab Limited has informed the Exchange about the transcript of Q1 FY27 earnings conference call, hosted by JM Financials, where the management discussed the company's operational and financial performance for the quarter.

Symbiotec Pharmalab Limited

Symbiotec Pharmalab Limited has informed the Exchange about the link of recording of their earnings conference call for Q1 ended June 30, 2026, available on their website and accessible via a provided link.

Symbiotec Pharmalab Limited

Symbiotec Pharmalab Limited has informed the Exchange about Copy of Newspaper Publication regarding Unaudited Financial Results for the quarter ended June 30, 2026.

Symbiotec Pharmalab Limited

Symbiotec Pharmalab Limited has announced its financial results for the quarter ended June 30, 2026, with steady performance in API business and growth expected in new businesses.

Symbiotec Pharmalab Limited

Symbiotec Pharmalab Limited has informed the Exchange about Investor Presentation for Q1FY27, highlighting steady API growth, licensing agreements, and regulatory audits.

Symbiotec Pharmalab Limited

Symbiotec Pharmalab Limited has informed the Exchange regarding Outcome of Board Meeting held on September 21, 2026. The Board of Directors considered and approved the Unaudited Standalone & Consolidated Financial Results for the quarter ended June 30, 2026. The trading window for dealing in the Company's securities shall remain closed until 48 hours from this announcement.

Symbiotec Pharmalab Limited

Symbiotec Pharmalab Limited has announced its unaudited financial results for the quarter ended June 30, 2026, and the trading window for dealing in the company's securities will remain closed until 48 hours from the announcement.

Symbiotec Pharmalab Limited

Symbiotec Pharmalab Limited has informed the Exchange regarding 'Update on Intimation under Regulation 8(2) of the Securities and Exchange Board of India(Prohibition of Insider Trading) Regulations, 2015'. The company has framed a Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information.

Symbiotec Pharmalab Limited

Symbiotec Pharmalab Limited has informed the Exchange regarding the authorization of Key Managerial Personnel to determine materiality of events or information and make disclosures to the stock exchange.

Symbiotec Pharmalab Limited

Symbiotec Pharmalab Limited has informed the Exchange regarding 'Intimation under Regulation 8(2) of the Securities Exchange Board of India (Prohibition of Insider Trading) Regulation 2015.' and enclosed the Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information.

Symbiotec Pharmalab Limited

Symbiotec Pharmalab Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015.